Actively Recruiting
Phase 1b Study of Tolododekin Alfa With Anti-PD-1PD-L1 Antibodies for Advanced Non-Small Cell Lung Cancer
Led by Ankyra Therapeutics, Inc · Updated on 2026-09-02
60
Participants Needed
11
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
This research evaluates tolododekin alfa also known as ANK-101 combined with an anti-PD-1PD-L1 antibody in people with advanced or metastatic non-small cell lung cancer NSCLC. It includes two groups one with participants who have progressed after prior standard treatments including anti-PD-1PD-L1 antibodies and chemotherapy, and another with participants who have not yet received treatment for locally advanced or metastatic NSCLC. Participants receive up to 8 cycles of tolododekin alfa administered as an intratumoral injection every 3 weeks. They also receive either cetrelimab or the investigators choice of an FDA-approved anti-PD-1PD-L1 antibody, both given every 3 weeks, for up to 1 year. The study compares these combinations in two parallel cohorts based on previous treatment history. Throughout the study, participants undergo assessments including tumor response evaluation using RECIST v1.1 criteria, safety monitoring for adverse events, and pharmacokinetic measurements of tolododekin alfa. Researchers measure outcomes like objective response rate, duration of response, disease control, progression-free survival, and overall survival over six months. Participants must provide fresh tumor biopsies and comply with study requirements during the treatment period, which may last up to one year.
CONDITIONS
Brief Title
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Research Team
A
Ankyra Therapeutics
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here